Lupin stock surge 2% on USFDA nod

Lupin logo

Lupin stock was up by 2% at Rs. 1064. The company has received final approval for its Nadolol tablets from USFDA to market generic version of US WorldMeds’ Cogard tablets.

The product is a generic version of US WorldMeds LLC’s Corgard tablets in the same strengths.

The tablets are indicated for management of patients with angina pectoris and for the treatment of hypertension.

The stock has hit a high of Rs.1070 and a low of Rs. 1050.